- Cardinal Health‘s forecast for adjusted earnings per share (EPS) in 2026 is set between $9.30 and $9.50, surpassing prior estimates of $9.26.
- For the fourth quarter, the company reported an adjusted EPS of $2.08, above the estimate of $2.04.
- Adjusted operating income for the quarter came in at $719 million, slightly below the expected $730.2 million.
- Reported revenue was $60.16 billion, which did not meet the estimated $60.92 billion.
- The Pharmaceutical and Healthcare Products division achieved revenue of $55.37 billion, while the Global Medical Products and Distribution segment generated $3.20 billion.
- Cash generated from operating activities was $1.53 billion in the fourth quarter.
- For the fiscal year 2026, the company has raised its non-GAAP diluted EPS outlook by $0.20 to a range of $9.30 to $9.50, reflecting a 13% to 15% growth.
- All five operating segments of Cardinal Health are showing double-digit profit growth, indicating strong operational performance and strategic execution.
- Analyst recommendations for Cardinal Health stand at 14 buys, 4 holds, and 0 sells.
“`
Cardinal Health on Smartkarma
Analyst coverage of Cardinal Health on Smartkarma reveals positive sentiments toward the company’s recent performance. Baptista Research, a prominent provider on the independent research network, highlights Cardinal Health‘s robust third-quarter fiscal year 2025 results. The company showed resilience and growth across its business segments, particularly driven by strong utilization trends in Pharmaceutical and Specialty Solutions. This success led to an increase in Cardinal Health‘s fiscal year 2025 EPS guidance. Baptista Research delves into factors influencing the company’s stock price and conducts an independent valuation using a Discounted Cash Flow (DCF) methodology.
A look at Cardinal Health Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Cardinal Health, Inc. is positioned for a promising long-term trajectory supported by its robust Smartkarma Smart Scores. With a stellar Growth score of 5, the company demonstrates impressive potential for expansion and development in the healthcare industry. This signifies Cardinal Health‘s ability to innovate, adapt, and seize opportunities for sustained growth in the market.
Furthermore, Cardinal Health exhibits strong Resilience, Momentum, and Dividend scores of 4 and 3 respectively, underlining its stability, positive market momentum, and commitment to rewarding shareholders. These scores collectively indicate a company that is well-positioned to weather challenges, capitalize on current trends, and provide steady returns to investors over the long run. Cardinal Health‘s diverse range of services, from pharmaceutical distribution to healthcare product manufacturing, further solidifies its standing as a key player in the healthcare sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
